The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Open accessAbstract
BACKGROUND: Controversy persists regarding the extent of shared pathways between arterial and venous thrombosis and whether treatments of known efficacy for one disease process have consistent benefits for the other. Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking. METHODS: We randomly assigned 17,802 apparently healthy men and women with both low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to receive rosuvastatin, 20 mg per day, or placebo. We followed participants for the first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data on an intention-to-treat basis. RESULTS: During a median follow-up period of 1.9 years (maximum, 5.0), symptomatic venous thromboembolism occurred in 94 participants: 34 in the rosuvastatin group and 60 in the placebo group. The rates of venous thromboembolism were 0.18 and 0.32 event per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio with rosuvastatin, 0.57; 95% confidence interval [CI], 0.37 to 0.86; P=0.007); the corresponding rates for unprovoked venous thromboembolism (i.e., occurring in the absence of a known malignant condition, trauma, hospitalization, or surgery) were 0.10 and 0.17 (hazard ratio, 0.61; 95% CI, 0.35 to 1.09; P=0.09) and for provoked venous thromboembolism (i.e., occurring in patients with cancer or during or shortly after trauma, hospitalization, or surgery), 0.08 and 0.16 (hazard ratio, 0.52; 95% CI, 0.28 to 0.96; P=0.03). The rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% CI, 0.25 to 0.79; P=0.004). Consistent effects were observed in all the subgroups examined. No significant differences were seen between treatment groups in the rates of bleeding episodes. CONCLUSIONS: In this trial of apparently healthy persons, rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism. (ClinicalTrials.gov number, NCT00239681.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citationSilverstein, M. D., Heit, J. A., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.585 · Cited by 2,660
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,641
Self-citationCardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis
Ageno, W., Becattini, C., Brighton, T., Selby, R., & Kamphuisen, P. W. (2008) · Circulation · doi:10.1161/circulationaha.107.709204 · Cited by 974
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169405 · Cited by 801
Grady, D., Wenger, N. K., Herrington, D., Khan, S., Furberg, C., Hunninghake, D., Vittinghoff, E., Hulley, S., & for the Heart and Estrogen/progestin Replacement Study Research Group (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00002 · Cited by 715
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Tsai, A. W., Cushman, M., Rosamond, W. D., Heckbert, S. R., Polak, J. F., & Folsom, A. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1182 · Cited by 700
An Association between Atherosclerosis and Venous Thrombosis
Prandoni, P., Bilora, F., Marchiori, A., Bernardi, E., Petrobelli, F., Lensing, A. W. A., Prins, M. H., & Girolami, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022157 · Cited by 652
A Prospective Study of Risk Factors for Pulmonary Embolism in Women
Goldhaber, S. Z. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540320044033 · Cited by 603
S⊘rensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A., & Prandoni, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61745-0 · Cited by 398
Glynn, R. J., & Rosner, B. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi309 · Cited by 380
Self-citationTsai, A. W., Cushman, M., Rosamond, W. D., Heckbert, S. R., Tracy, R. P., Aleksic, N., & Folsom, A. R. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01345-1 · Cited by 376
Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells
Sen-Banerjee, S., Mir, S., Lin, Z., Hamik, A., Atkins, G. B., Das, H., Banerjee, P., Kumar, A., & Jain, M. K. (2005) · Circulation · doi:10.1161/circulationaha.104.525774 · Cited by 354
Hansson, P.-O., Eriksson, H., Welin, L., Svärdsudd, K., & Wilhelmsen, L. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1886 · Cited by 310
Undas, A., Brummel-Ziedins, K. E., & Mann, K. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000151647.14923.ec · Cited by 275
Smeeth, L., Douglas, I., Hall, A. J., Hubbard, R., & Evans, S. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03308.x · Cited by 234
Use of Statins and the Subsequent Development of Deep Vein Thrombosis
Ray, J. G., Mamdani, M., Tsuyuki, R. T., Anderson, D. R., Yeo, E. L., & Laupacis, A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1405 · Cited by 207
SØRENSEN, H. T., HORVATH-PUHO, E., SØGAARD, K. K., CHRISTENSEN, S., JOHNSEN, S. P., THOMSEN, R. W., PRANDONI, P., & BARON, J. A. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03279.x · Cited by 167
Ridker, P. M., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Khurmi, N. S., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.072 · Cited by 125
Self-citationSelective prescribing led to overestimation of the benefits of lipid-lowering drugs
Glynn, R. J., Schneeweiß, S., WANG, P., LEVIN, R., & Avorn, J. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.12.012 · Cited by 119
Self-citationHigh-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism
Eichinger, S., Pecheniuk, N. M., Hron, G., Deguchi, H., SCHEMPER, M., Kyrle, P. A., & Griffin, J. H. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.08.005 · Cited by 113
RAMCHARAN, A. S., van Stralen, K. J., Snoep, J. D., Mantel-Teeuwisse, A. K., Rosendaal, F. R., & Doggen, C. J. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03235.x · Cited by 104
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women
Doggen, C. J. M., Lemaître, R. N., Smith, N. L., Heckbert, S. R., & Psaty, B. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00696.x · Cited by 78
Statins and the risk of idiopathic venous thromboembolism
Yang, C., Jick, S. S., & Jick, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01523.x · Cited by 74
Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism
Glynn, R. J., Ridker, P. M., Goldhaber, S. Z., & Buring, J. E. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00004 · Cited by 71
Self-citationLacut, K., Oger, E., Gal, G. L., Couturaud, F., Louis, S., Leroyer, C., & Mottier, D. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00252.x · Cited by 69
Chamberlain, A. M., Folsom, A. R., Heckbert, S. R., et al. (2008) · Blood · doi:10.1182/blood-2008-05-157412 · Cited by 60
Kaba, N. K., Francis, C. W., Moss, A. J., Zaręba, W., Oakes, D., Knox, K. L., Fernandez, I. D., & Rainwater, D. L. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00658.x · Cited by 44
Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women
Everett, B. M., Glynn, R. J., Buring, J. E., & Ridker, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03302.x · Cited by 43
Self-citationArterial disease and venous thrombosis: are they related, and if so, what should we do about it?
Lowe, G. D. O. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02130.x · Cited by 39
Cited by
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationHeart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citation
Metadata
- Authors
- Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Ridker, P. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-30
- Volume
- 360
- Issue
- 18
- Pages
- 1851-1861
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1593008417
- Cited by
- 752
- References
- 36
- FWCI
- 61.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.